By Bhanvi Satija LONDON, April 1 (Reuters) - Vaccine makers Pfizer and BioNTech halted a large U.S. trial of their updated ...

The trial is tied to a post-marketing commitment that FDA Commissioner Martin Makary put in place last year for all approved ...

Pfizer BioNTech halt COVID vaccine study in adults 50-64 due to slow enrollment, citing inability to generate relevant postmarketing data.

Pfizer and BioNTech have paused a large U.S. clinical trial designed to test their updated COVID-19 vaccine in healthy adults ...

COVID-19 partners Pfizer and BioNTech have been unable to recruit healthy adults aged 50 to 64 fast enough to deliver ...

The move comes as COVID vaccine ‌makers grapple ‌with pushback from the U.S. administration and weak U.S. demand for the ...

A Belgian court on Wednesday ordered Poland and Romania to take delivery of 1.9 billion euros ($2.2 billion) worth of ...

Pfizer (PFE) stock and BioNTech (BNTX) stock are in focus as a large U.S. trial for the companies' updated COVID-19 vaccine ...

Pfizer Inc. (NYSE:PFE) is included among the 15 Cheapest Stocks with Highest Dividends. On April 1, Reuters reported that a ...

Pfizer has emerged victorious in a legal brawl with Poland and Romania over contested COVID vaccine orders, with a Belgian ...

BioNTech will wind up its vaccine manufacturing plant in Singapore by February 2027 after a strategic review. Read more at ...

The Trump administration has also pushed back against Covid vaccine recommendations, and the FDA toughened its requirements ...